Paper - WANFANG MED ONLINE

You Position: Home > Paper

Intestinal absorption barrier and novel strategies for absorption enhancement

( views:275, downloads:6 )

Author:: No author available

Journal Title:: ACTA PHARMACEUTICA SINICA

Issue:: 7

DOI:: 10.3321/j.issn:0513-4870.2005.07.004

Key Word:: 肠道;吸收屏障;促吸收

Abstract： @@ 胃肠道屏障是机体的重要保护系统,可阻止毒物及抗原的吸收,但也是限制药物吸收的主要因素,导致许多药物的口服生物利用度低,同时也是造成许多具有较好生物活性的候选化合物不能进入后续开发研究的根本原因.

Reference

[1]Bing-Wei Sun,Xiao-Chen Zhao,Guang-ji WANG,etc.Hormonal regulation of dipeptide transporter (PepT1) in Caco-2 cells with normal and anoxia/reoxygenation management[J].2003,(4).
[2]陈建海,陈清元,沈家瑞,等.结肠定位给药系统载体的设计、合成及降解性能的研究[J].2004,(3).
[3]魏农农,陆彬.结肠定位壳聚糖包衣氟尿嘧啶脂质体的制备、形态与体外释放[J].2003,(1).
[4]平其能.纳米药物和纳米载体系统[J].2002,(1).
[5]刘辉,潘卫三,杜蓉,等.几种酶抑制剂对胰岛素肠道吸收的影响[J].2004,(2).
[6]王堃,仲来福.肠道CYP3A和P-gp：口服药物的吸收屏障[J].2003,(11).
[7]C D, Britten,S D, Baker,L J, Denis,etc.Oral paclitaxel and concurrent cyclosporin A: targeting clinically relevant systemic exposure to paclitaxel.[J].2000,6(9).
[8]Carino GP.,Jacob JS.,Mathiowitz E..Nanosphere based oral insulin delivery[J].2000,65(1).
[9]F, De Jaeghere,E, Allémann,R, Cerny,etc.pH-Dependent dissolving nano- and microparticles for improved peroral delivery of a highly lipophilic compound in dogs.[J].2001,3(1).
[10]K S, Lown,D G, Bailey,R J, Fontana,etc.Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression.[J].1997,99(10).
[11]Hershfield MS.Genotype is an important determinant of phenotype in adenosine deaminase deficiency.[J].2003,15(5).
[12]Rost KL,Guerret M,Kovarik JM,etc.Longitudinal assessment of a P-glycoprotein-mediated drug interaction of valspodar on digoxin.[J].1999,66(4).
[13]Meier, C..Pro-Nucleotides - Recent Advances in the Design of Efficient Tools for the Delivery of Biologically Active Nucleoside Monophosphates[J].1998,1(3).
[14]J M, Meerum Terwogt,M M, Malingré,J H, Beijnen,etc.Coadministration of oral cyclosporin A enables oral therapy with paclitaxel.[J].1999,5(11).
[15]Zhang Y,Benet LZ.The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein.[J].2001,40(3).
[16]Y, Nishioka,H, Yoshino.Lymphatic targeting with nanoparticulate system.[J].2001,47(1).
[17]El Shabouri MH.Positively charged nanoparticles for improving the oral bioavailability of cyclosporin-A.[J].2002,249(1).
[18]Amidon GL,Lee HJ.The effect of enzyme inhibitor and absorption site following (D-ala2, D-leu5)enkephalin oral administration in rats.[J].2002,23(4).
[19]Mackay, M.,Phillips, J.,Hastewell, J..Peptide drug delivery: Colonic and rectal absorption[J].1997,28(2).
[20]Edward L. LeCluyse,Steven C. Sutton.In vitro models for selection of development candidates. Permeability studies to define mechanisms of absorption enhancement[J].1997,23(1-3).
[21]Charman, W. N.,Porter, C. J. H..Lipophilic prodrugs designed for intestinal lymphatic transport[J].1996,19(2).
[22]Hunter, J.,Hirst, B. H..Intestinal secretion of drugs. The role of P-glycoprotein and related drug efflux systems in limiting oral drug absorption[J].1997,25(2).
[23]Yu DK.The contribution of P-glycoprotein to pharmacokinetic drug-drug interactions.[J].1999,39(12).
[24]Roden DM,Cvetkovic M,Wandel C,etc.Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein.[J].1999,16(3).
[25]M Thanou,J.C Verhoef,H.E Junginger.Chitosan and its derivatives as intestinal absorption enhancers[J].2001,50(1).
[26]Krise, J. P.,Stella, V. J..Prodrugs of phosphates, phosphonates, and phosphinates[J].1996,19(2).